SLC5A2 and urinary bladder carcinoma: Other potential adverse effects were also taken into account such as the risk of cardiac failure, factures, and bladder cancer associated with thiazolidinediones 35-37 and that of urogenital tract infections associated with SGLT2 inhibitors 38.